Long-term use of afalaza in patients with BPH: influence on the symptoms and risk of progression
- Autores: Pushkar D.Y.1,2, Kolontarev K.B.1,2, Bernikov A.N.1,2
-
Afiliações:
- Moscow Urological Center of S.P. Botkin City Clinical Hospital
- FGBOU VO “Russian University of Medicine”
- Edição: Nº 6 (2024)
- Páginas: 60-63
- Seção: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/680277
- DOI: https://doi.org/10.18565/urology.2024.6.61-64
- ID: 680277
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Introduction. The widespread prevalence of BPH among men leads to an increase in urination disorders, a decrease in the quality of life, and an increased risk of surgical intervention. The introduction of long-term conservative therapy into clinical practice can improve the quality of life and reduce the number of prostate procedures.
Aim. To obtain additional data on the efficiency of Afalaza during long-term use in patients with BPH.
Materials and methods. A retrospective analysis of 99 patients with a diagnosis of BPH, aged over 40 years, who received Afalaza monotherapy for more than a year, was performed. The IPSS questionnaire was used to assess LUTS, while the transabdominal US, transrectal US and MRI were performed to measure the prostate volume. Statistical analysis was done using ANCOVA analysis. Covariates included age, duration of therapy in months, and duration of therapy by category (IPSS, prostate volume).
Results. An average age of patients was 50.8±6.9 years. The average duration of therapy was 26 months (11 to 41 months). The average IPSS score decreased from 13.3±3.6 (13, 6, 19) to 9.4±3.1 points (9, 6, 18). The average change in the IPSS score was 3.8±2.7 points (4, -6, 9) (F1/99=203.8, p<0.0001). The duration of therapy influenced on the reduction in the severity of lower urinary tract symptoms (F1/99=8.75, p=0.0039). Treatment results did not depend on the age of the patients (F1/99=0.01, p=0.9172). The average prostate volume decreased from 39.9±6.1 cc (40, 30, 60) to 38.0±6.1 cc (38, 28, 58). Delta was 1.9±1.0 cc (F1/99=364.85, p<0.0001). There were neither acute urinary retention nor the need for surgical treatment. According to outpatient records, there were no adverse events when taking Afalaza.
Conclusion. Long-term use of Afalaza is effective in improving the quality of life of patients with BPH and can be recommended for long-term therapy to prevent progression and surgical intervention. The drug requires further study in various groups of patients with BPH.
Palavras-chave
Texto integral
Sobre autores
D. Pushkar
Moscow Urological Center of S.P. Botkin City Clinical Hospital; FGBOU VO “Russian University of Medicine”
Email: Pushkardm@mail.ru
ORCID ID: 0000-0002-6096-5723
Academician of RAS, Ph.D., MD, Professor, Head of the Department of Urology, Honored Doctor of the Russia, Honored Scientist of Russia, Chief urologist of the Ministry of Health of Russia
Rússia, Moscow; MoscowK. Kolontarev
Moscow Urological Center of S.P. Botkin City Clinical Hospital; FGBOU VO “Russian University of Medicine”
Email: kb80@yandex.ru
ORCID ID: 0000-0003-4511-5998
Ph.D., MD, professor at the Department of Urology
Rússia, Moscow; MoscowA. Bernikov
Moscow Urological Center of S.P. Botkin City Clinical Hospital; FGBOU VO “Russian University of Medicine”
Autor responsável pela correspondência
Email: bernikov@mac.com
ORCID ID: 0000-0001-8361-585X
Ph.D., associate professor at the Department of Urology
Rússia, Moscow; MoscowBibliografia
- GBD 2019 Benign Prostatic Hyperplasia Collaborators. Global, regional, and national burden of benign prostatic hyperplasia, 2000–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754-e776. doi: 10.1016/S2666-7568(22)00213-6.
- Apolikhin O.I., Sivkov A.V., Yanenko E.K., Katibov M.I., Zolotukhin O.V., Shaderkin I.A., Prosyannikov M.Y., Voitko D.A., Tsoi A.A., Galiev N.A., Kastrikin Y.V. Frequency of acute urinary retention as an indicator of quality of medical care for patients with prostatic adenoma. Urologiia. 2016;2:43–48. Russian (О.И. Аполихин, А.В. Сивков, Э.К. Яненко, М.И. Катибов, О.В. Золотухин, И.А. Шадеркин, М.Ю. Просянников, Д.А. Войтко, А.А. Цой, Н.А. Галиев, Ю.В. Кастрикин. Частота выявления острой задержки мочи как индикатор качества оказания медицинской помощи пациентам с аденомой предстательной железы. Урология. 2016;(2):43–48).
- Instructions for the medical use of the drug Afalaza. LP-no. (000021)-(RG-RU)-260422 (electronic resource.) URL: https://grls.rosminzdrav.ru / (date of access: 08.11.2024). Russian (Инструкция по медицинскому применению препарата Афалаза. ЛП-№ (000021)-(РГ-RU)-260422 (электронный ресурс.) URL: https://grls.rosminzdrav.ru/ (дата обращения: 08.11.2024)).
- General Pharmacopoeia article of the State Pharmacopoeia of the Russian Federation XV edition of the OFS. 1.7.0001. Biological medicines obtained on the basis of graduated technology. Date of introduction 01.09.2023. (Electronic resource.) URL: https://pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/1/1-9/biologicheskie-lekarstvennye-preparaty-poluchennye-na-osnove-gradualnoy-tekhnologii / (date of access: 08.11.2024). Russian (Общая фармакопейная статья Государственной фармакопеи Российской Федерации XV издания ОФС. 1.7.0001. Биологические лекарственные препараты, полученные на основе градуальной технологии. Дата введения 01.09.2023. (Электронный ресурс.) URL: https://pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/1/1-9/biologicheskie-lekarstvennye-preparaty-poluchennye-na-osnove-gradualnoy-tekhnologii/ (дата обращения: 08.11.2024)).
- Pushkar D., Vinarov A., Spivak L., Kolontarev K., Putilovskiy M., Andrianova E., Epstein O. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial. Cent European J Urol. 2018;71(4):427-435. doi: 10.5173/ceju.2018.1803.
- Kupriyanov Y.A., Rasner P.I., Rokhlikov I.M., Akrikidi A.A., Soloviev V.V., Markov A.A., Nozdrin E.V., Logvinov L.A., Vasilevskiy R.P., Skrupskiy K.S., Pushkar D.Yu., Putilovskiy M.A., Epstein O.I. The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-nave patients with benign prostatic hyperplasia. Urologiia. 2019;(3):36–42. Russian (Куприянов Ю.А., Раснер П.И., Рохликов И.М., Акрикиди А.А., Соловьев В.В., Марков А.А., Ноздрин Е.В., Логвинов Л.А., Василевский Р.П., Скрупский К.С., Пушкарь Д.Ю., Путиловский М.А., Эпштейн О.И. Опыт применения препарата Афалаза для лечения симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы без предшествовавшей терапии. Урология. 2019;(3):36–42).
- Clinical recommendations – Benign prostatic hyperplasia – 2020-2021-2022 (01/31/2023) – Approved by the Ministry of Health of the Russian Federation (Electronic resource.) URL:http://disuria.ru/_ld/13/1392_kr20N40MZ.pdf (date of application: 08.11.2024). Russian (Клинические рекомендации – Доброкачественная гиперплазия предстательной железы – 2020-2021-2022 (31.01.2023) – Утверждены Минздравом РФ (Электронный ресурс.) URL:http://disuria.ru/_ld/13/1392_kr20N40MZ.pdf (дата обращения: 08.11.2024)).
Arquivos suplementares
